WO2021211961A1 - Regenerative nonsteroidal anti-inflammatory compositions, methods of production, and methods of use thereof - Google Patents

Regenerative nonsteroidal anti-inflammatory compositions, methods of production, and methods of use thereof Download PDF

Info

Publication number
WO2021211961A1
WO2021211961A1 PCT/US2021/027674 US2021027674W WO2021211961A1 WO 2021211961 A1 WO2021211961 A1 WO 2021211961A1 US 2021027674 W US2021027674 W US 2021027674W WO 2021211961 A1 WO2021211961 A1 WO 2021211961A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
cells
cell
syndrome
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/027674
Other languages
English (en)
French (fr)
Inventor
Ramon CORONADO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crown Scientific LLC
Original Assignee
Crown Scientific LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Scientific LLC filed Critical Crown Scientific LLC
Priority to CA3175599A priority Critical patent/CA3175599A1/en
Priority to EP21788592.0A priority patent/EP4135729A4/en
Priority to JP2022563025A priority patent/JP2023522213A/ja
Priority to US17/919,453 priority patent/US20230190821A1/en
Priority to AU2021257255A priority patent/AU2021257255A1/en
Publication of WO2021211961A1 publication Critical patent/WO2021211961A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Definitions

  • the placenta may comprise at least one placental tissue selected from amniotic membrane, chorion membrane, chorionic villus, umbilical cord, and Wharton's Jelly.
  • the placenta may preferably be selected from at least one of amniotic membrane and/or chorion membrane.
  • the at least one placental tissue may comprise perinatal stromal cells (PSCs) and/or mesenchymal stromal cells (MSCs).
  • PSCs perinatal stromal cells
  • MSCs mesenchymal stromal cells
  • the RNSA composition may be stable in solution at room temperature for at least eight weeks.
  • the RNSA composition may be stable to lyophilization.
  • the present disclosure also generally encompasses a method for producing a cell-free or substantially cell-free regenerative nonsteroidal anti-inflammatory (RNSA) composition.
  • the method may comprise (i) obtaining at least one placental tissue from at least one mammal selected from human, non-human primate, pig, sheep, horse, cow, dog, cat, rat, and mouse, wherein the at least one placental tissue is selected from amniotic membrane, chorion membrane, chorionic villus, umbilical cord, and Wharton's Jelly, and wherein the at least one placental tissue comprises perinatal stromal cells (PSCs); (ii) optionally isolating the PSCs from said placental tissue and culturing the PSCs in at least one cell culture medium; (iii) permitting apoptosis of said placental tissue and PSCs comprised therein and/or permitting apoptosis of PSCs isolated therefrom to naturally occur and/or inducing
  • the method may further comprise conducting one or more screening assays to assess the effects of the isolated apoptotic extract or one or more portions thereof on the proliferation of activated T cells and/or the proliferation of one or more cells selected from stromal cells, mesenchymal stromal cells (MSCs), parenchymal cells, and tenocytes and/or on the expression of pro-inflammatory cytokines and/or the expression of anti-inflammatory cytokines in a mammalian subject or in vitro.
  • MSCs mesenchymal stromal cells
  • tenocytes and/or on the expression of pro-inflammatory cytokines and/or the expression of anti-inflammatory cytokines in a mammalian subject or in vitro.
  • inducing apoptosis may comprise (i) replacing the at least one cell culture medium with a non-cell culture medium; and (ii) incubating the cultured MSCs in the non-cell culture medium in an air-tight environment at a temperature ranging from about 4 °C to about 42 °C, preferably at about 37 °C, for about 3 days to about 5 days, preferably for about 4 days, wherein the incubating optionally comprises agitation.
  • the cultured PSCs may be cultured to at least 80% confluence.
  • the method may further comprise washing the cultured MSCs with phosphate-buffered saline (PBS) prior to inducing apoptosis.
  • PBS phosphate-buffered saline
  • the method may further comprise centrifugation at about 10,000 x g for about 30 minutes.
  • the present disclosure also generally relates to a cell-free or substantially cell-free regenerative nonsteroidal anti-inflammatory (RNSA) composition produced by the methods described herein.
  • RNSA regenerative nonsteroidal anti-inflammatory
  • the composition may be non-cytotoxic for one or more cell types selected from stromal cells, mesenchymal stromal ells (MSCs), parenchymal cells, and tenocytes in a subject, in vivo, or in vitro.
  • cell types selected from stromal cells, mesenchymal stromal ells (MSCs), parenchymal cells, and tenocytes in a subject, in vivo, or in vitro.
  • the composition may be capable of promoting proliferation of one or more cell types selected from stromal cells, mesenchymal stromal cells (MSCs), parenchymal cells, and tenocytes in a subject, in vivo, or in vitro.
  • stromal cells mesenchymal stromal cells (MSCs)
  • MSCs mesenchymal stromal cells
  • parenchymal cells parenchymal cells
  • tenocytes tenocytes
  • the one or more pro-inflammatory cytokines may be selected from TNFa, NFKB, IL17A, IL-6, and IFNy.
  • the composition may be capable of increasing cAMP production from activated T cells in a subject, in vivo, or in vitro.
  • the at least one inflammatory condition or disease may be an acute or chronic condition associated with inflammation, e.g,, an acute or chronic autoimmune disease associated with acute or chronic inflammation, optionally a viral or bacterial or fungal infection associated with acute or chronic inflammation, further optionally a hepatitis virus, ZIKA virus, herpes, papillomavirus, influenza virus, or coronavirus, further optionally COVID-19 or SARS.
  • an acute or chronic autoimmune disease associated with acute or chronic inflammation optionally a viral or bacterial or fungal infection associated with acute or chronic inflammation, further optionally a hepatitis virus, ZIKA virus, herpes, papillomavirus, influenza virus, or coronavirus, further optionally COVID-19 or SARS.
  • the at least one inflammatory condition or disease may be selected from pneumonia, single or multiple organ failure or dysfunction, sepsis, cytokine storm, fever, neurological dysfunction or impairment, loss of taste or smell, cardiac dysfunction, pulmonary dysfunction, liver dysfunction, acute or chronic respiratory dysfunction, graft versus host disease (GVHD), cardiomyopathy, vasculitis, fibrosis, ophthalmic inflammation, dermatologic inflammation, gastrointestinal inflammation, tendinopathies, allergy, asthma, glomerulonephritis, pancreatitis, hepatitis, inflammatory arthritis, gout, multiple sclerosis, psoriasis, Acute Respiratory Distress Syndrome (ARDS), wound healing, diabetic ulcers, non-healing wounds, lupus, and other autoimmune diseases associated with acute or chronic inflammation.
  • GVHD graft versus host disease
  • cardiomyopathy vasculitis
  • fibrosis ophthalmic inflammation
  • dermatologic inflammation gastrointestinal inflammation
  • tendinopathies allergy, asthma, glomeruloneph
  • the ophthalmic inflammation may comprise one or more of corneal regeneration, corneal wound healing, corneal melting, dry eye, ocular infection, eyelid sty, and autoimmune-associated peripheral ulcerative keratitis.
  • the subject may have been diagnosed with or is suspected of having a coronavirus infection, optionally COVID-19.
  • the subject may have been diagnosed with a coronavirus infection, optionally COVID-19, and is on a respirator, has Acute Respiratory Distress Syndrome, and/or is experiencing respiratory difficulties.
  • the subject may have been diagnosed with or suspected of having a coronavirus infection, optionally COVID-19, and optionally the subject comprises one or more risk factors that place the subject at higher risk for morbidity or a poor treatment outcome, e.g., age over 55 years, obesity, diabetes, cardiac problem or condition, respiratory condition, optionally asthma, COPD, cystic fibrosis, is a smoker, is a heavy drinker, has lupus, has elevated blood pressure, has cancer, receives chemotherapy, has (chronic) kidney disease and/or is on dialysis, or any combination of the foregoing.
  • a coronavirus infection optionally COVID-19
  • the subject comprises one or more risk factors that place the subject at higher risk for morbidity or a poor treatment outcome, e.g., age over 55 years, obesity, diabetes, cardiac problem or condition, respiratory condition, optionally asthma, COPD, cystic fibrosis, is a smoker, is a heavy drinker, has lupus, has elevated blood pressure, has cancer, receive
  • FIG. 8 presents data showing activated T cell proliferation as a model for inflammation and results from testing the effect of DNase, RNase, and Proteinase K on the potency of the RNSA composition produced from cultured hMSCs described in Example 2.
  • FIG. 11 presents data showing activated T cell proliferation as a model for inflammation and results from testing the effect of tissue type and culture media on the potency of the RNSA composition produced from tissue extractions described in Example 1.
  • FIG. 16 presents data showing activated CD4+/CD8+ T cell proliferation within a PBMC sample as a model for inflammation and results from testing the effect of the tissue extraction process described in Example 1 ("AM”) compared to the cultured MSCs extraction process described in Example 2 (“BR”) on the potency of the RNSA compositions.
  • AM tissue extraction process described in Example 1
  • BR cultured MSCs extraction process described in Example 2
  • FIG. 17 presents data showing activated CDllc+ T cell proliferation within a PBMC sample as a model for inflammation and results from testing the effect of the tissue extraction process described in Example 1 ("AM”) compared to the cultured MSCs extraction process described in Example 2 (“BR”) on the potency of the RNSA compositions.
  • FIG. 20 shows that the RNSA composition reduces the expression level of TNFa from activated PBMCs.
  • FIG. 21 shows that the RNSA composition reduces the expression level of NFKB from activated PBMCs.
  • FIG. 22 shows that the RNSA composition reduces the expression level of IL-17A from activated PBMCs.
  • FIG. 24 shows that the RNSA composition promotes/induces cAMP production by activated T cells.
  • FIG. 25 shows results of the eicosanoid analysis of RNSA compositions.
  • FIG. 26 shows a list of eicosanoids which were not detected in the eicosanoid analysis of RNSA compositions.
  • FIG. 27 shows proliferation of human stromal cells as a model for regeneration and promotion of stromal cell proliferation by the RNSA composition.
  • the steroid is completely cytotoxic.
  • FIG. 30 shows proliferation of human tenocytes as a model for regeneration and promotion of human tenocytes proliferation by the RNSA composition.
  • the tested commercial compounds were each cytotoxic to varying degrees.
  • FIG. 31 shows data relating to survival proportions for a mouse model of Graft versus Host Disease.
  • FIG. 32 is a plot of the GvHD score versus normalized days for the GvHD mice injected with media (PBMC) or with an exemplary cell-free regenerative nonsteroidal antiinflammatory composition (Cell-Free) according to the invention.
  • PBMC media
  • Cell-Free exemplary cell-free regenerative nonsteroidal antiinflammatory composition
  • FIG. 35 is a photo of the GvHD mice.
  • a GvHD mouse treated with an exemplary RNSA composition according to the invention is shown on the left whereas an untreated GvHD mouse is shown on the right.
  • FIG. 37 shows plots quantifying the inflammatory markers histopathology disease scores (H&E) and the Trichrome fibrosis scores at Day 21 in a mouse model of cardiomyopathy.
  • FIG. 38 shows a photo of a human patient having eczema on the left hand on Day 1 and a photo of the same on Day 60 after a first subcutaneous injection of an exemplary RNSA composition according to the invention on Day 1 and a second subcutaneous injection of the same RNSA composition on Day 30.
  • FIG. 39 shows an ultrasound image of a human ankle tendinosis prior to treatment (subcutaneous injection of an exemplary RNSA composition according to the invention at the site of tendinosis) and an ultrasound image of the healed tendon 30 days after treatment.
  • FIG. 40 shows two photos of a human patient having an eyelid sty prior to treatment with eye drops comprising an exemplary RNSA composition according to the invention (top) and two photos of the same eye six weeks after treatment showing that the sty had completely healed (bottom).
  • words of approximation such as, without limitation, "about,” “substantial” or “substantially” refers to a condition that when so modified is understood to not necessarily be absolute or perfect but would be considered close enough to those of ordinary skill in the art to warrant designating the condition as being present.
  • the extent to which the description may vary will depend on how great a change can be instituted and still have one of ordinary skill in the art recognize the modified feature as still having the required characteristics and capabilities of the unmodified feature.
  • a numerical value herein that is modified by a word of approximation such as "about” may vary from the stated value by at least ⁇ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15%.
  • A, B, C, or combinations thereof is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB.
  • expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, AB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth.
  • BB BB
  • AAA AAA
  • AB BBC
  • AAABCCCCCC CBBAAA
  • CABABB CABABB
  • apoptosis refers to programmed cell death via a highly-regulated, genetically-directed process of cell self-destruction that is marked by the fragmentation of nuclear DNA, is activated either by the presence of a stimulus or removal of a suppressing agent or stimulus and is a normal physiological process.
  • cell-free generally refers to a composition or extract, e.g., a placental derived extract, wherein all cells originally contained in the composition or extract have been removed or rendered non-viable. In the present invention this is generally achieved by inducing apoptosis such as by use of nutrient deprivation and removal of live and/or apoptosed cells such as by the use of decantation, centrifugation, and/or filtration.
  • non-cell culture medium generally refers to a medium wherein cells are cultured that lacks cells and which moreover may lack nutrients which may induce nutrient deprivation, apoptosis, and/or hypoxia of cells contained therein, e.g., a saline medium or composition.
  • a "therapeutically effective amount" of an agent refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result, such as for treatment of a disease, condition, or disorder, and/or pharmacokinetic or pharmacodynamic effect of the treatment.
  • the response is either amelioration of symptoms in a patient or a desired biological outcome (e.g., reduction of tissue fibrosis, reduction of tissue inflammation, increase of immune modulation).
  • the therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the subject.
  • the provided methods involve administering the compositions at effective amounts, e.g., therapeutically effective amounts alone or in combination with other active agents or therapies.
  • Pharmaceutically acceptable carriers, excipients or stabilizers are well known in the art, for example Remington's Pharmaceutical Sciences, 16th edition, Osol, A. Ed. (1980). Pharmaceutically acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and may include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid, vitamin A, vitamin E, and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3- pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum
  • the pharmaceutical composition may also contain other therapeutic agents, and may be formulated, for example, by employing conventional vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, preservatives, etc.) according to techniques known in the art of pharmaceutical formulation.
  • the pharmaceutical composition may further contain additional pharmaceutical or therapeutic agent, as evaluated beneficial by the physician administering said pharmaceutical composition.
  • the cell-free or substantially cell-free regenerative nonsteroidal anti-inflammatory (RNSA) compositions derived from placenta may be specifically derived from placental "perinatal stromal cells” (PSCs), also referred to herein as mesenchymal stromal cells (MSCs) or which may comprise MSCs.
  • PSCs peripheral stromal cells
  • MSCs mesenchymal stromal cells
  • the cell-free or substantially cell-free regenerative nonsteroidal anti-inflammatory (RNSA) compositions described herein may be derived from non-placental MSCs obtained from, e.g., bone marrow, adipose tissue, muscle, corneal stroma, and/or deciduous teeth dental pulp, i.e., "adult" MSCs.
  • RNSA regenerative nonsteroidal anti-inflammatory
  • the human placenta includes an umbilical cord, an amniotic membrane (amnion), and a "placenta proper", which includes the chorion or chorionic plate, the villus, the intervillous space, the basal plate and the cotyledon. Each portion of the placenta can be isolated and can be used to derive subpopulations of perinatal stromal cells.
  • the placental tissue may be obtained from a single donor. In some embodiments, the placental tissue may be obtained from more than one donor (pooled donor placental tissue sample).
  • the placenta may comprise at least one placental tissue selected from amniotic membrane, chorion membrane, chorionic villus, umbilical cord, and Wharton's Jelly. In preferred embodiments, the placenta may comprise at least one placental tissue selected from amniotic membrane and/or chorion membrane.
  • the amnion membrane can be mechanically separated from the chorion, which leads to the derivation of amnion perinatal stromal cell (APSC).
  • APSC amnion perinatal stromal cell
  • the umbilical cord exposes Wharton's jelly, containing umbilical arteries and vein.
  • Wharton's Jelly perinatal stromal cell WPSC, WJPSC, or MJ-MSC
  • WPSC, WJPSC, or MJ-MSC Wharton's Jelly perinatal stromal cell
  • the remaining portion of the placenta which can be referred to as the placenta proper, can be used directly to prepare placenta proper stromal cell (PPSC), or can be further separated.
  • the chorionic membrane can be detached to isolate whole chorion derived stromal cell (CSC), and the intermediate and terminal villi can be exposed to isolate chorionic-villi stromal cell (CVC).
  • the at least one placental tissue may comprise perinatal stromal cells (PSCs) and/or mesenchymal stromal cells (MSCs).
  • PSCs perinatal stromal cells
  • MSCs mesenchymal stromal cells
  • the RNSA composition may elicit an anti-inflammatory response.
  • the RNSA composition may be capable of inhibiting proliferation of activated T cells in a subject, in vivo, or in vitro, wherein the T cells are CD4+, CD8+, CD4+/CD8+, CDllc+, CDllb+, and/or CD56+ T cells.
  • the RNSA composition may be capable of promoting proliferation of one or more cells selected from stromal cells, mesenchymal stromal cells (MSCs), parenchymal cells, and tenocytes in a subject, in vivo, or in vitro.
  • MSCs mesenchymal stromal cells
  • tenocytes tenocytes
  • the RNSA composition may be capable of reducing expression of one or more pro-inflammatory cytokines from activated peripheral blood mononucleated cells (PBMCs) and/or activated T cells and/or of promoting the expression or activity of one or more anti-inflammatory cytokines in a subject, in vivo, or in vitro.
  • the one or more pro-inflammatory cytokines may be selected from TNFa, NFKB, IL17A, IL-6, and IFNy.
  • the RNSA composition may be capable of increasing cAMP production from activated T cells in a subject, in vivo, or in vitro.
  • the present disclosure also generally encompasses a method for producing a cell-free or substantially cell-free regenerative nonsteroidal anti-inflammatory (RNSA) composition.
  • the method may comprise (i) obtaining at least one placental tissue from a mammal selected from human, non-human primate, pig, sheep, horse, cow, dog, cat, rat, and mouse, wherein the at least one placental tissue is selected from amniotic membrane, chorion membrane, chorionic villus, umbilical cord, and Wharton's Jelly, and wherein the at least one placental tissue comprises perinatal stromal cells (PSCs); (ii) optionally isolating the PSCs from said placental tissue and culturing the PSCs in at least one cell culture medium (iii) permitting apoptosis of said placental tissue and PSCs comprised therein and/or permitting apoptosis of PSCs isolated therefrom to occur naturally and/or inducing or enhancing a
  • the method may further comprise conducting one or more screening assays to assess the effects of the isolated apoptotic extract or one or more portions thereof on the proliferation of activated T cells and/or the proliferation of one or more cells selected from stromal cells, mesenchymal stromal cells (MSCs), parenchymal cells, and tenocytes and/or on the expression of pro-inflammatory cytokines and/or the expression of anti-inflammatory cytokines in a mammalian subject, in vivo, or in vitro.
  • MSCs mesenchymal stromal cells
  • tenocytes and/or on the expression of pro-inflammatory cytokines and/or the expression of anti-inflammatory cytokines in a mammalian subject, in vivo, or in vitro.
  • inducing apoptosis may comprise serum deprivation, nutrient deprivation, and/or hypoxia.
  • inducing apoptosis may comprise (i) contacting the placental tissue with a non-cell culture medium in a ratio ranging from about 1 mL non-cell culture medium per 1 gram of placental tissue to about 100 mL non-cell culture medium per 1 gram of placental tissue, preferably in a ratio of about 10 mL non-cell culture medium per 1 g of placental tissue; and (ii) incubating the placental tissue in the non-cell culture medium in an air-tight environment at a temperature ranging from about 4 °C to about 42 °C, preferably at about 37 °C, for about 2 days to about 12 days, preferably for about 10 days, wherein the incubating optionally comprises agitation, for example, at about 90 rpm.
  • apoptosis may alternatively be induced or enhanced by other methods known in the art for initiating or promoting apoptosis.
  • the method mayfurther comprise washingthe placental tissue with phosphate-buffered saline (PBS) prior to inducing apoptosis. In some embodiments, the method may further comprise mincing the placental tissue prior to inducing apoptosis. In some embodiments, the method may further comprise contacting the placental tissue with one or more antimicrobial agents.
  • PBS phosphate-buffered saline
  • the method may further comprise isolating the placental tissue PSCs and culturing the PSCs in at least one cell culture medium prior to inducing apoptosis.
  • inducing apoptosis may comprise (i) replacing the at least one cell culture medium with a non-cell culture medium; and (ii) incubating the cultured PSCs in the non-cell culture medium in an air-tight environment at a temperature ranging from about 4 °C to about 42 °C, preferably at about 37 °C, for about 3 days to about 5 days, preferably for about 4 days, wherein the incubating optionally comprises agitation.
  • the cultured PSCs may be cultured to at least 80% confluence.
  • the non-cell culture medium may comprise saline solution.
  • the saline solution may comprise 0.9% NaCl.
  • the saline solution may comprise phosphate-buffered saline (PBS).
  • PBS phosphate-buffered saline
  • the air-tight environment may prevent gas exchange, thereby inducing a hypoxic environment.
  • the method may further comprise washing the cultured PSCs with phosphate-buffered saline (PBS) prior to inducing apoptosis.
  • PBS phosphate-buffered saline
  • the method may further comprise centrifugation at about 10,000 x g for about 30 minutes.
  • the method may further comprise filtration through a 0.45 pm membrane. In some embodiments, the method may further comprise filtration through a 0.2 pm membrane, i.e. sterile filtration. In some embodiments, the method may further comprise filtration through a 30 KDa MWCO membrane, a 10 KDa MWCO membrane, a 5 KDa MWCO membrane, a 3 KDa MWCO membrane, and/or a 2 KDa MWCO membrane.
  • the present disclosure also generally relates to a cell-free or substantially cell-free regenerative nonsteroidal anti-inflammatory (RNSA) composition produced by any of the methods disclosed herein.
  • RNSA regenerative nonsteroidal anti-inflammatory
  • a method of treatment of at least one inflammatory condition or disease or at least one symptom associated therewith may comprise administering a therapeutically or prophylactically effective amount of the cell-free or substantially cell-free regenerative nonsteroidal anti inflammatory (RNSA) composition described herein to a subject in need thereof wherein such treatment optionally may reduce or prevent tissue inflammation in the subject.
  • RNSA regenerative nonsteroidal anti inflammatory
  • a molecular marker of inflammation in the tissue is decreased as compared to said molecular marker in the tissue before the administration of the RNSA composition.
  • the molecular marker of inflammation is selected from the group consisting of TNFa expression, NFKB expression, INFy expression, IL- 17 (or IL-17A) expression, IL-6 expression, and a combination thereof.
  • the at least one inflammatory condition or disease may be an acute or chronic condition associated with inflammation, e.g., an acute or chronic autoimmune disease associated with acute or chronic inflammation, optionally a viral or bacterial or fungal infection associated with acute or chronic inflammation, further optionally a hepatitis virus, ZIKA virus, herpes, papillomavirus, influenza virus, or coronavirus, further optionally COVID-19 or SARS.
  • an acute or chronic autoimmune disease associated with acute or chronic inflammation optionally a viral or bacterial or fungal infection associated with acute or chronic inflammation, further optionally a hepatitis virus, ZIKA virus, herpes, papillomavirus, influenza virus, or coronavirus, further optionally COVID-19 or SARS.
  • the at least one inflammatory condition or disease may be an acute inflammatory condition or disease, e.g., an acute inflammatory autoimmune condition or infectious condition associated with acute inflammation such as a viral condition associated with acute inflammation, further optionally a coronavirus infection, e.g., COVID-19 or SARS.
  • an acute inflammatory condition or disease e.g., an acute inflammatory autoimmune condition or infectious condition associated with acute inflammation such as a viral condition associated with acute inflammation, further optionally a coronavirus infection, e.g., COVID-19 or SARS.
  • the at least one inflammatory condition or disease or symptom associated therewith may be selected from pneumonia, single or multiple organ failure or dysfunction, sepsis, cytokine storm, fever, neurological dysfunction or impairment, loss of taste or smell, cardiac dysfunction, pulmonary dysfunction, liver dysfunction, acute or chronic respiratory dysfunction, graft versus host disease (GVHD), cardiomyopathy, vasculitis, fibrosis, ophthalmic inflammation, dermatologic inflammation, gastrointestinal inflammation, tendinopathies, allergy, asthma, glomerulonephritis, pancreatitis, hepatitis, inflammatory arthritis, gout, multiple sclerosis, psoriasis, Acute Respiratory Distress Syndrome (ARDS), wound healing, diabetic ulcers, non-healing wounds, lupus, and at least one autoimmune disease associated with acute or chronic inflammation.
  • GVHD graft versus host disease
  • cardiomyopathy vasculitis
  • fibrosis ophthalmic inflammation
  • dermatologic inflammation gastrointestinal inflammation
  • tendinopathies allergy,
  • the at least one inflammatory condition or disease may be pneumonia, e.g., caused by at least one virus, fungus, bacterium or a combination thereof.
  • the pneumonia may be Covid-19-associated and/or influenza-associated pneumonia.
  • Coronavirus Disease 2019 or Covid-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 coronavirus).
  • SARS-CoV-2 coronavirus severe acute respiratory syndrome coronavirus 2
  • the predominant CT findings of Covid-19-associated pneumonia patients include conspicuous ground-glass opacification, consolidation, bilateral involvement, and peripheral and diffuse distribution.
  • the at least one inflammatory condition or disease may comprise COVID-19 or other inflammatory condition or infection and the treatment or prevention may further comprise the administration of at least one other active, e.g., an anti-inflammatory agent such as an anti-inflammatory antibody or anti inflammatory fusion protein, e.g., Embrel (etanercept), Humira (adalimumab), or an IL-6 antagonist, an antiviral agent, an antibacterial agent, an antifungal agent, an analgesic, an anti-congestive agent, an anti-fever agent, or a combination of any of the foregoing.
  • an anti-inflammatory agent such as an anti-inflammatory antibody or anti inflammatory fusion protein
  • Embrel etanercept
  • Humira adalimumab
  • an IL-6 antagonist an antiviral agent
  • an antibacterial agent e.g., an antifungal agent, an analgesic, an anti-congestive agent, an anti-fever agent, or a combination of any of the
  • the treated subject has been diagnosed with or suspected of having a coronavirus infection, optionally COV!D-19, and the subject comprises one or more risk factors that place the subject at higher risk for morbidity or a poor treatment outcome, e.g., age over 55 years, obesity, diabetes, cardiac problem or condition, respiratory condition, optionally asthma, COPD, cystic fibrosis, is a smoker, is a heavy drinker, has lupus, has elevated blood pressure, has cancer, receives chemotherapy, has (chronic) kidney disease and/or is on dialysis, or any combination of the foregoing.
  • a coronavirus infection optionally COV!D-19
  • the subject comprises one or more risk factors that place the subject at higher risk for morbidity or a poor treatment outcome, e.g., age over 55 years, obesity, diabetes, cardiac problem or condition, respiratory condition, optionally asthma, COPD, cystic fibrosis, is a smoker, is a heavy drinker, has lupus, has elevated blood pressure, has cancer, receive
  • the ophthalmic inflammation may comprise one or more of corneal regeneration, corneal wound healing, corneal melting, dry eye, ocular infection, eyelid sty, and autoimmune-associated peripheral ulcerative keratitis.
  • the at least one inflammatory condition or disease may be fibrosis.
  • the fibrosis may comprise pulmonary fibrosis, cystic fibrosis, idiopathic pulmonary fibrosis, interstitial pulmonary fibrosis, radiation- induced lung injury, liver fibrosis, bridging fibrosis of the liver, cirrhosis, glial scar, arterial stiffness, arthrofibrosis, Crohn's disease, Dupuytren's contracture, keloid fibrosis, Mediastinal fibrosis, Myelofibrosis, Myocardial fibrosis, Peyronie's disease, Nephrogenic systemic fibrosis, Progressive massive fibrosis, pneumoconiosis, Retroperitoneal fibrosis, stromal fibrosis, Scleroderma, systemic sclerosis, chronic obstructive pulmonary disease (COPD), asthma, and adhesive capsulitis.
  • COPD chronic obstructive pulmonary disease
  • the at least one inflammatory condition or disease may be gastrointestinal inflammation.
  • the gastrointestinal inflammation may comprise inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS), and Celiac disease.
  • the composition may be administered by one or more of injection, optionally intravenous (IV) or subcutaneous (SC) administration, nebulization, and/or eye drops.
  • IV intravenous
  • SC subcutaneous
  • the subject may be selected from a human, non-human primate, pig, sheep, horse, cow, dog, cat, rat, and mouse. In preferred embodiments, the subject may be human.
  • the method of treatment or prevention may further comprise the administration of at least one other active, e.g., an anti-inflammatory agent such as an anti-inflammatory antibody or anti-inflammatory fusion protein, an antiviral agent, an antibacterial agent, an antifungal agent, an analgesic, an anti-congestive agent, an anti-fever agent, or a combination of any of the foregoing.
  • an anti-inflammatory agent such as an anti-inflammatory antibody or anti-inflammatory fusion protein
  • an antiviral agent such as an antibacterial agent, an antifungal agent, an analgesic, an anti-congestive agent, an anti-fever agent, or a combination of any of the foregoing.
  • an anti-inflammatory agent such as an anti-inflammatory antibody or anti-inflammatory fusion protein
  • an antiviral agent such as an antibacterial agent, an antifungal agent, an analgesic, an anti-congestive agent, an anti-fever agent, or a combination of any of the foregoing.
  • an an anti-inflammatory agent such as an anti
  • the subject may have been diagnosed with or is suspected of having a coronavirus infection, optionally COVID-19.
  • the subject may have been diagnosed with a coronavirus infection, optionally COVID-19, and is on a respirator, has Acute Respiratory Distress Syndrome, and/or is experiencing respiratory difficulties.
  • the subject may have been diagnosed with or suspected of having a coronavirus infection, optionally COVID-19, and optionally the subject comprises one or more risk factors that place the subject at higher risk for morbidity or a poor treatment outcome, e.g., age over 55 years, obesity, diabetes, cardiac problem or condition, respiratory condition, optionally asthma, COPD, cystic fibrosis, is a smoker, is a heavy drinker, has lupus, has elevated blood pressure, has cancer, receives chemotherapy, has (chronic) kidney disease and/or is on dialysis, or any combination of the foregoing.
  • a coronavirus infection optionally COVID-19
  • the subject comprises one or more risk factors that place the subject at higher risk for morbidity or a poor treatment outcome, e.g., age over 55 years, obesity, diabetes, cardiac problem or condition, respiratory condition, optionally asthma, COPD, cystic fibrosis, is a smoker, is a heavy drinker, has lupus, has elevated blood pressure, has cancer, receive
  • amniotic membrane was mechanically separated from the chorion and umbilical cord and subsequently washed extensively with phosphate- buffered saline (PBS) with 1% PrimocinTM (Invivogen) (FIG. 1A-C). The amniotic membrane was separated in an Erlenmeyer flask.
  • PBS phosphate- buffered saline
  • PrimocinTM Invivogen
  • amniotic membrane or chorion membrane, or chorionic villus, or Wharton's Jelly/umbilical cord tissue
  • a 0.9% NaCl saline solution in an air-tight environment (a capped Erlenmeyer flask) at 37 °C for 10 days with gentle agitation at 90 rpm to induce apoptosis of amniotic membrane cells (i.e., amniotic membrane- derived mesenchymal stromal cells).
  • the supernatant was decanted from the placental tissue and was centrifuged at 10,000 x g for 30 min.
  • the supernatant was then filtered through a 0.45 pm membrane and then through a 0.22 pm membrane (VWR) or directly through a 0.22 pm membrane (Pall) to obtain the cell-free or substantially cell-free regenerative nonsteroidal anti-inflammatory composition ("RNSA").
  • the RNSA composition was stored at -80 °C until use.
  • Human perinatal stromal cells which comprise human mesenchymal stromal cells (hMSCs) were obtained from the placentas described in Example 1 as follows.
  • the amnion membrane was mechanically separated from the chorion and washed extensively with phosphate-buffered saline (PBS). It was then minced into small pieces and digested with TrypLE (Gibco, Waltham, MA, USA) at 5 mL/g of tissue for 30 min in a shaker incubator (124 Incubator Shaker series, New Brunswick Scientific, Edison, NJ, USA) at 37 °C, 150 rpm to remove the amniotic epithelial cells.
  • PBS phosphate-buffered saline
  • the undigested amnion was then removed, washed with PBS and further digested with 125 U/mg Collagenase I (Worthington, Lakewood, NJ, USA) at 37 °C, 150 rpm for 1.5 h to isolate the amniotic mesenchymal cells (APSC).
  • the mobilized cells in the digest were passed through a 100 mih cell strainer (VWR, Radnor, PA, USA) and collected by centrifugation at 500 x g for 8 min.
  • the Wharton's Jelly was extracted from the umbilical cord as follows: the umbilical cord was sectioned in approximately 1.5 cm in length pieces and then dissected longitudinally to expose the Wharton's Jelly. The arteries and vein were removed, the remaining tissue was minced into small pieces, and digested with 125 U/mg Collagenase I at 37 °C, 150 rpm for 2.5 h or until all tissue was digested. The digest was passed through a 100 pm cell strainer and centrifuged at 500 x g for 8 min.
  • the chorion was mechanically separated from the amnion membrane and washed extensively with phosphate-buffered saline (PBS).
  • PBS phosphate-buffered saline
  • the chorion membrane was then minced into small pieces and digested with 125 U/mg Collagenase I (Worthington, Lakewood, NJ, USA) at 37 °C, 150 rpm for 1.5 h in a shaker incubator (124 Incubator Shaker series, New Brunswick Scientific, Edison, NJ, USA) to isolate the chorion stromal cells (CSCs).
  • CSCs chorion stromal cells
  • the mobilized cells in the digest were passed through a 100pm cell strainer (VWR, Radnor, PA, USA) and collected by centrifugation at 500 x g for 8 min.
  • VSCs chorionic villi stromal cells
  • PSCs Perinatal Stromal Cells isolated herein had similar characteristics of Mesenchymal Stromal Cells (MSCs) based on the ISCT criteria, which is being plastic adherent under standard culture conditions, expression of CD105+, CD73+, CD90+, CDllb-, and CD45- HLADR.
  • MSCs Mesenchymal Stromal Cells
  • All PSCs were positive (>70%) for CD273+ (PD-L2), CD210+ (IL-10 Receptor) and negative ( ⁇ 5%) for CD178- (FasL), CD119- (IFNg Receptor), CD85d- (ILT4) and CD40. These additional immune-regulatory markers could be used to extend the characterization panel to identify such cells.
  • hMSCs derived from the amniotic membrane, Wharton's Jelly, chorion membrane and chorionic villus were each cultured using standard procedures known in the art.
  • 10.5 million cultured hMSCs were expanded in a PBS Biotech MINI Bioreactor (RoosterBio) utilizing SynthemaxTM II Microcarrier beads (Corning), which the cells adhere to, and 450 mL Rooster Media (Rooster Basal Media supplemented with Rooster Media Booster (RoosterBio)) with agitation at 25 rpm. Daily samples were taken to determine the number of cells per bead by fluorescence microscopy with DAPI staining.
  • the cultured and expanded hMSCs were then incubated in 500 mL 0.9% NaCI saline solution in an air-tight environment at 37 °C for about 4 days with gentle agitation (30 rpm) to induce apoptosis. After about 4 days, greater than 95% of the cells will have undergone apoptosis as determined using fluorescence microscopy and staining with the LIVE/DEADTM Viability/Cytotoxicity Kit (ThermoFisher). The liquid was then decanted and filtered through a 0.22 pm membrane to obtain the cell-free regenerative nonsteroidal anti-inflammatory composition ("RNSA"). The RNSA composition was stored at -80 °C until use.
  • RNSA cell-free regenerative nonsteroidal anti-inflammatory composition
  • the activated and expanded T lymphocytes described above are a model for inflammation in which the normalized T cell proliferation represents 100% (FIG. 2).
  • FIG. 2 When the activated T cells are cultured in the presence of MSCs, inhibition of T cell proliferation of greater than 85% is observed (FIG. 2), representing a positive control for the inhibition of inflammation.
  • Numerous tissues and conditions for treating those tissues were explored to determine a cell-free regenerative anti-inflammatory composition, including the amniotic membrane tissue and apoptotic condition described in Example 1 to produce the cell-free RNSA, shown in FIG. 2 as "C14.”
  • the results for eighteen other conditions in which a cell-free composition was prepared and tested for its ability to inhibit activated T cell proliferation are also shown in FIG. 2.
  • the protocol for generating the RNSA from amniotic membrane described in Example 1 was altered such that various means of cell death were tested.
  • the amniotic tissue was subjected to a hypoxia condition for 72 hours, an apoptotic condition for 24 hours or 48 hours, or to IFN gamma and Poly(hC) dsRNA for 24 hours or 48 hours.
  • a hypoxia condition for 72 hours
  • an apoptotic condition for 24 hours or 48 hours
  • IFN gamma and Poly(hC) dsRNA for 24 hours or 48 hours.
  • FIG. 4 none of these conditions produced an RNSA composition which inhibited activated T cell proliferation. This is in contrast to the amniotic membrane RNSA composition described in Example 1, which was produced using an apoptotic condition for 10 hours (FIG. 2 and FIG. 3).
  • the T cell proliferation assay was also used to determine the effect of filtration on the potency of the RNSA composition.
  • the RNSA composition was centrifuged at 350 x g or filtered through membranes of various size cutoffs, including 5 pm, 0.45 pm, 0.2 pm, 2 KDa MWCO and 10 KDa MWCO, as shown in FIG. 5. Also tested were a 10 KDa - 100 KDa filtration supernatant, and isolated exosomes "exos" from the supernatant, also shown in FIG. 5.
  • the RNSA composition produced from amniotic membrane- derived hMSCs expanded in the PBS bioreactor ("BR PBS") described in Example 2 was used in these tests.
  • the T cell proliferation assay was also used to determine the effect of lyophilization on the potency of the RNSA composition.
  • the RNSA composition produced using cultured amnion hMSCs from Example 2 was used.
  • Native RNSA samples of 200 pL, 150 pL, and 100 pL were compared to the same volume of native RNSA samples which were lyophilized and then resuspended in the equivalent volume of deionized water or 10-fold lower volume of deionized water. As shown in FIG. 6, lyophilization did not inhibit the bioactivity of the RNSA composition.
  • the T cell proliferation assay was also used to determine the effect of proteases, DNase, and RNase on the potency of the RNSA composition.
  • the potency of the RNSA composition produced from amniotic membrane tissue extraction described in Example 1 was not affected by DNase, RNase, or Proteinase K, suggesting a lipid nature for the bioactive compound(s).
  • the potency of the RNSA composition produced from cultured hMSCs described in Example 2 was not affected by DNase, RNase, or Proteinase K.
  • a similar T cell viability assay was used to determine that Proteinase K, DNase, and RNase do not affect the potency of the RNSA composition produced from amniotic membrane tissue extraction described in Example 1.
  • the T cell proliferation assay was also used to determine the effect of time during extraction and shaking vs. non-shaking conditions on the potency of the RNSA composition produced from amniotic membrane tissue extraction described in Example 1. As shown in FIG. 10, better extraction uniformity was achieved when waiting until Day 10. Also shown in FIG. 10, there was not a big effect from shaking vs. non-shaking when waiting until Day 10.
  • the T cell proliferation assay was also used to determine the effect of tissue type (AM -amniotic membrane, CH- chorion membrane, Villi -chorionic villus, WJ -Wharton's Jelly/Umbilical cord tissue) on the potency of the RNSA composition produced from the placental tissue extractions described in Example 1.
  • tissue type AM -amniotic membrane, CH- chorion membrane, Villi -chorionic villus, WJ -Wharton's Jelly/Umbilical cord tissue
  • the effect of the culture media (AlphaMEM, OptiMEM, and PBS) was also tested. As shown in FIG. 11, the RNSA compositions produced from amniotic membrane tissue extraction in PBS and from chorion membrane tissue extraction in PBS had the highest potency.
  • the T cell proliferation assay was also used to determine the effect of various concentrations of the EP2, EP3, and EP4 receptor blockers on the potency of the RNSA composition. As shown in FIG. 13, the EP receptor blockers did not affect the potency of the RNSA composition.
  • a modified version of the T cell proliferation assay was utilized in which T cells were not isolated from the PBMCs. Rather, PBMCs were activated with the CD3/CD28/CD2 T cell activator and proliferation of CD4+ T cells was monitored.
  • This modified proliferation assay was used to determine the effect of the tissue extraction process described in Example 1 ("AM") compared to the cultured MSCs extraction process described in Example 2 ("BR"), as shown in FIG. 14, on the potency of the RNSA compositions.
  • FIG. 15 shows the same modified T cell proliferation assay except that proliferation of CD8+ T cells was monitored.
  • FIG. 16 shows the same modified T cell proliferation assay except that proliferation of CD4+/CD8+ T cells was monitored.
  • FIG. 20 shows that the RNSA composition reduces the expression level of TNFa from activated PBMCs.
  • FIG. 21 shows that the RNSA composition reduces the expression level of NFKB from activated PBMCs.
  • FIG. 22 shows that the RNSA composition reduces the expression level of IL-17A from activated PBMCs.
  • FIG. 23 shows that the RNSA composition reduces the expression level of IFNy from activated PBMCs.
  • FIG. 24 shows that the RNSA composition promotes / induces cAMP production by activated T cells.
  • Various samples were analyzed by mass spectrometry to determine the identity and concentrations of eicosanoid compounds in the RNSA composition.
  • the analyzed samples included three samples extracted in aMEM media (cxMEM-1, aMEM-2, and aMEM-3) which served as negative controls.
  • Four RNSA composition samples produced using the cultured hMSCs described in Example 2 (BR-1, BR-2, BR-3, and BR- 4) and three RNSA composition samples produced using the amniotic membrane extraction protocol described in Example 1 (CM-1, CM-2, and CM-3) were also analyzed.
  • Results of the eicosanoid analysis are shown in FIG. 25.
  • CM-1, CM-2, and CM-3 RNSA compositions are enriched for several eicosanoids compared to the aMEM and BR samples. Further, the CM samples inhibited T cell proliferation and reduced T cell viability, whereas the BR samples inhibited T cell proliferation to a lesser extent and did not reduce T cell viability.
  • CM-1, CM-2, and CM-3 RNSA compositions are enriched for several eicosanoids compared to the aMEM and BR samples.
  • the CM samples inhibited T cell proliferation and reduced T cell viability
  • the BR samples inhibited T cell proliferation to a lesser extent and did not reduce T cell viability.
  • Several eicosanoid analytes were not detected in any of the analyzed samples, which compounds are shown in FIG. 26.
  • the regenerative properties of the RNSA composition were tested using human parenchymal cells. As shown in FIG. 29, the RNSA composition promotes proliferation whereas the tested commercial compounds were each cytotoxic to varying degrees.
  • FIG. 32 is a plot of the GvHD score versus normalized days for the GvHD mice injected with media (PBMC) or with an exemplary cell-free regenerative nonsteroidal anti inflammatory composition (Cell-Free) according to the invention.
  • PBMC media
  • Cell-Free exemplary cell-free regenerative nonsteroidal anti inflammatory composition
  • FIG. 34A is a photo of GvHD mouse model kidneys. The kidney on the left from the control mouse is enlarged indicating it is inflamed and likely fibrotic, whereas the kidney on the right is from the GvHD mouse treated with the RNSA composition. The kidney on the right looks normal.
  • FIG. 34B is a plot of the GvHD mouse kidney areas in mm 2 .
  • FIG. 35 is a photo of the GvHD mice.
  • a GvHD mouse treated with an exemplary RNSA composition according to the invention is shown on the left whereas an untreated GvHD mouse is shown on the right.
  • the RNSA composition reduced inflammatory markers IL-17 and IFNy in vivo at Day 21 and Day 42 as determined using an ELISpot assay compared to the untreated control mouse (PBS) (FIG. 36).
  • the RNSA composition also reduced inflammatory markers histopathology disease scores and Trichrome fibrosis scores at Day 21 compared to the untreated control mouse (FIG. 37).
  • Example 6 Evaluation of the Effect of Cell-Free Regenerative Nonsteroidal Antiinflammatory (RNSA) Compositions on Eczema
  • FIG. 40 shows two photos of the patient's eye having the eyelid sty prior to the treatment (top) and two phots of the same eye six weeks after treatment showing the eyelid had fully healed (bottom). The patient did not receive any other treatment or procedure for the eyelid sty.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
PCT/US2021/027674 2020-04-17 2021-04-16 Regenerative nonsteroidal anti-inflammatory compositions, methods of production, and methods of use thereof Ceased WO2021211961A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA3175599A CA3175599A1 (en) 2020-04-17 2021-04-16 Regenerative nonsteroidal anti-inflammatory compositions, methods of production, and methods of use thereof
EP21788592.0A EP4135729A4 (en) 2020-04-17 2021-04-16 REGENERATING NON-STEROID ANTI-INFLAMMATORY COMPOSITIONS, METHODS OF PRODUCTION THEREOF AND METHODS OF USE THEREOF
JP2022563025A JP2023522213A (ja) 2020-04-17 2021-04-16 再生非ステロイド性抗炎症組成物、その生産方法、及び使用方法
US17/919,453 US20230190821A1 (en) 2020-04-17 2021-04-16 Regenerative nonsteroidal anti-inflammatory compositions, methods of production, and methods of use thereof
AU2021257255A AU2021257255A1 (en) 2020-04-17 2021-04-16 Regenerative nonsteroidal anti-inflammatory compositions, methods of production, and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011373P 2020-04-17 2020-04-17
US63/011,373 2020-04-17

Publications (1)

Publication Number Publication Date
WO2021211961A1 true WO2021211961A1 (en) 2021-10-21

Family

ID=78084637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/027674 Ceased WO2021211961A1 (en) 2020-04-17 2021-04-16 Regenerative nonsteroidal anti-inflammatory compositions, methods of production, and methods of use thereof

Country Status (6)

Country Link
US (1) US20230190821A1 (cg-RX-API-DMAC10.html)
EP (1) EP4135729A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023522213A (cg-RX-API-DMAC10.html)
AU (1) AU2021257255A1 (cg-RX-API-DMAC10.html)
CA (1) CA3175599A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021211961A1 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023119063A1 (en) * 2021-12-24 2023-06-29 Ehj Ip Limited Placental composition
CN116626303A (zh) * 2023-03-17 2023-08-22 重庆医科大学 槲皮素通过scap/srebp2/nlrp3通路减轻脂多糖诱导的急性肺损伤的影响
EP4281089A4 (en) * 2021-02-26 2025-02-12 Arugula Sciences LLC Villi stromal cells compositions and uses thereof
EP4561595A4 (en) * 2022-07-26 2026-07-29 Biostem Tech Inc COMPOSITIONS BASED ON HUMAN UMBILICAL CORD AND INTRA-ARTICULAR THERAPY METHODS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150010609A1 (en) * 2010-02-18 2015-01-08 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
US20180280444A1 (en) * 2016-06-10 2018-10-04 Batu Biologics, Inc. Nanoparticle based tumor endothelial targeting vaccine
WO2019169141A1 (en) * 2018-02-28 2019-09-06 Lester Smith Medical Research Institute Production and use of extracellular vesicles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103356710A (zh) * 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
KR20160147058A (ko) * 2014-05-07 2016-12-21 오시리스 쎄라퓨틱스, 인크. 치료적 태반 조성물, 이의 제조방법 및 사용방법
GB2568603A (en) * 2017-11-06 2019-05-22 King S College London Therapeutic substances, their preparation and diagnostic procedure
US20200397990A1 (en) * 2018-02-28 2020-12-24 Regents Of The University Of Minnesota Multi-compartment syringe with pump mechanism
CN112955543A (zh) * 2018-06-11 2021-06-11 法国汉氏联合公司(法国H&B) 源自间充质干细胞的细胞外囊泡

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150010609A1 (en) * 2010-02-18 2015-01-08 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
US20180280444A1 (en) * 2016-06-10 2018-10-04 Batu Biologics, Inc. Nanoparticle based tumor endothelial targeting vaccine
WO2019169141A1 (en) * 2018-02-28 2019-09-06 Lester Smith Medical Research Institute Production and use of extracellular vesicles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4135729A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4281089A4 (en) * 2021-02-26 2025-02-12 Arugula Sciences LLC Villi stromal cells compositions and uses thereof
WO2023119063A1 (en) * 2021-12-24 2023-06-29 Ehj Ip Limited Placental composition
JP2024544108A (ja) * 2021-12-24 2024-11-28 イーエイチジェイ アイピー リミテッド 胎盤組成物
EP4561595A4 (en) * 2022-07-26 2026-07-29 Biostem Tech Inc COMPOSITIONS BASED ON HUMAN UMBILICAL CORD AND INTRA-ARTICULAR THERAPY METHODS
CN116626303A (zh) * 2023-03-17 2023-08-22 重庆医科大学 槲皮素通过scap/srebp2/nlrp3通路减轻脂多糖诱导的急性肺损伤的影响

Also Published As

Publication number Publication date
US20230190821A1 (en) 2023-06-22
JP2023522213A (ja) 2023-05-29
AU2021257255A1 (en) 2022-11-24
EP4135729A1 (en) 2023-02-22
EP4135729A4 (en) 2024-07-31
CA3175599A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
US20230190821A1 (en) Regenerative nonsteroidal anti-inflammatory compositions, methods of production, and methods of use thereof
JP7580202B2 (ja) 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法
US10722541B2 (en) Methods for treating radiation or chemical injury
RU2562154C2 (ru) Амниотические адгезивные клетки
JP7549355B2 (ja) 間葉系間質細胞を拡大するための方法
US20140017209A1 (en) Methods for treating radiation or chemical injury
JP2011500045A (ja) Tr1細胞、間葉系幹細胞およびその使用
CN107708811A (zh) 治疗性汇集的血液凋亡细胞制剂与其用途
US20230121245A1 (en) Regenerative nonsteroidal anti-inflammatory compositions, methods of production, and methods of use thereof
AU2017328913A1 (en) Macrophage-based therapy for use in the treatment of liver injury
JP2023522213A5 (cg-RX-API-DMAC10.html)
CN111286488B (zh) 一种自然杀伤细胞体外培养方法
WO2023119239A1 (en) Method of treating severe graft versus host disease
WO2023200882A1 (en) Compositions and methods for treating post acute sequelae of sars-cov-2 infection (long covid)
EP3160480B1 (en) Mesenchymal stromal cells for treating rheumatoid arthritis
WO2014089397A1 (en) Compositions and methods of treating and preventing pulmonary fibrosis
CN118620839A (zh) 一种用于提高无血清环境下nk细胞扩增和杀伤活性的培养基和方法
US20210338740A1 (en) Therapeutic methods and compositions
JP2010509360A (ja) 幹細胞移植を補助するためにALDHbr細胞を使用する方法
CN107034217A (zh) 启动子、重组间质干细胞及其制备方法和应用
JP2021528100A (ja) 抗炎症特性を有する新規タンパク質
US20150037303A1 (en) Cells, compositions, and treatment methods for stimulation of hematopoiesis
WO2024133886A1 (en) Primed mesenchymal stem cells for use in the treatment of chronic kidney disease
Gonzaga et al. Non-Viral Therapy in COVID-19: Where Are We Standing? Towards Cell Therapy Approaches for Long COVID Patients
CN121754685A (zh) 一种用于治疗关节炎症的双重修饰外泌体、制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21788592

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022563025

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3175599

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021788592

Country of ref document: EP

Effective date: 20221117

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021257255

Country of ref document: AU

Date of ref document: 20210416

Kind code of ref document: A

WWW Wipo information: withdrawn in national office

Ref document number: 2021788592

Country of ref document: EP